Business Description
Evofem Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US30048L3024
Total Employee Number:
29Description
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | -10.43 | |||||
Debt-to-Equity | -0.68 | |||||
Debt-to-EBITDA | -17.57 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -181.52 | |||||
Beneish M-Score | -5.22 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -95.6 | |||||
3-Year Book Growth Rate | 80 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.91 | |||||
9-Day RSI | 46.5 | |||||
14-Day RSI | 49.62 | |||||
3-1 Month Momentum % | -7.06 | |||||
6-1 Month Momentum % | -14.32 | |||||
12-1 Month Momentum % | -14.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.08 | |||||
Quick Ratio | 0.05 | |||||
Cash Ratio | 0.02 | |||||
Days Inventory | 138.92 | |||||
Days Sales Outstanding | 84.98 | |||||
Days Payable | 944.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -404.8 | |||||
Shareholder Yield % | -589.91 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 76.96 | |||||
Operating Margin % | -17.08 | |||||
Net Margin % | -29.8 | |||||
EBITDA Margin % | -14.76 | |||||
FCF Margin % | -1.25 | |||||
OCF Margin % | -1.24 | |||||
ROA % | -43.83 | |||||
ROIC % | -5.05 | |||||
3-Year ROIIC % | -766.08 | |||||
ROC (Joel Greenblatt) % | -596.03 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.05 | |||||
EV-to-EBIT | -15.06 | |||||
EV-to-EBITDA | -17.43 | |||||
EV-to-Revenue | 2.57 | |||||
EV-to-Forward-Revenue | 3.32 | |||||
EV-to-FCF | -205.72 | |||||
Price-to-GF-Value | 0.82 | |||||
Earnings Yield (Greenblatt) % | -6.64 | |||||
FCF Yield % | -23.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:EVFM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evofem Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20.237 | ||
| EPS (TTM) ($) | -0.05 | ||
| Beta | -0.3215 | ||
| 3-Year Sharpe Ratio | -1.2 | ||
| 3-Year Sortino Ratio | -1.32 | ||
| Volatility % | 47.97 | ||
| 14-Day RSI | 49.62 | ||
| 14-Day ATR ($) | 0.001095 | ||
| 20-Day SMA ($) | 0.00851 | ||
| 12-1 Month Momentum % | -14.13 | ||
| 52-Week Range ($) | 0.0008 - 0.02 | ||
| Shares Outstanding (Mil) | 132.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evofem Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evofem Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-26 09:00 | In 135 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 30 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.01 (-1.49%) | ||
| Annual report for 2025 | 2026-03-11 | 0.01 (-5.32%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-11 | 0.01 (-5.32%) | ||
| General meeting for 2025 | 2025-11-26 09:00 | 0.01 (-17.50%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 0.01 (+8.98%) | ||
| Evofem Biosciences Special Meeting of Stockholders | 2025-09-26 09:00 | 0.01 (-3.86%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.01 (+2.65%) |
Show
Entries
Evofem Biosciences Inc Frequently Asked Questions
What is Evofem Biosciences Inc(EVFM)'s stock price today?
The current price of EVFM is $0.01. The 52 week high of EVFM is $0.02 and 52 week low is $0.00.
When is next earnings date of Evofem Biosciences Inc(EVFM)?
The next earnings date of Evofem Biosciences Inc(EVFM) is 2026-08-14 Est..
Does Evofem Biosciences Inc(EVFM) pay dividends? If so, how much?
Evofem Biosciences Inc(EVFM) does not pay dividend.
Guru Commentaries on OTCPK:EVFM
No articles.
Press Release
Articles on Evofem Biosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers